ERBB2 and breast carcinoma: Here we calculate TC death rates that correspond to two clinical scenarios: 1) HER2-positive breast cancer in which there is a complete or partial response to a short duration (40 days) of HER2-targeted therapy, and 2) HER2-negative breast cancer in which there is no appreciable short-term response to HER2-targeted therapy.